Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While TB-500 is studied for enhancing musculoskeletal and cardiac repair, wound healing, and promoting cell migration and differentiation via actin cytoskeleton remodeling21255, Tirzepatide is approved for type 2 diabetes and obesity, producing larger HbA1c and body-weight reductions than semaglutide in head-to-head trials24.
While TB-500 works as a synthetic peptide comprising the LKKTETQ actin-binding motif of thymosin beta-4 that binds G-actin, sequesters actin monomers, and promotes cell migration, angiogenesis, and tissue repair1255, Tirzepatide is a 39-amino-acid synthetic peptide primarily based on GIP sequence with C20 fatty diacid conjugation that acts as a dual agonist at GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite24.
TB-500
TMSB4X
Tirzepatide
Not assigned in the current dataset.
TB-500 and Tirzepatide are noticeably different, with limited direct overlap in their usual biological context. Both are often discussed in Cardiovascular health contexts, while TB-500 is more of a signal peptide and Tirzepatide is better described as a metabolic peptide and Hormone peptide. Their biological logic is quite different: TB-500 is a signaling modulator and a growth factor mimetic, whereas Tirzepatide is a receptor agonist and a hormone analog. Both are synthetic in origin and their development context also differs, with TB-500 in Preclinical development while Tirzepatide is approved. TB-500 takes the form of a linear peptide, whereas Tirzepatide is closer to a peptide conjugate, Tirzepatide incorporates lipidation and d-amino acid substitution features that are not part of TB-500; while their sequence patterns also diverge, with TB-500 showing protein-mimetic sequence features and Tirzepatide showing alpha-helical domain features.